Prices of Dukarb, Rosuzet cut 3 yrs through PVA

prices were cut 3 consecutive years through PVA 'Type C' negotiations

Products show strong performance for 3 years... price cut rate reduced by 30% for Korean innovative pharmaceutical companies

The insurance ceiling price of 6 drugs has been cut for 3 consecutive years through the price-volume agreement ‘Type C’ negotiations.

 

According to the industry on the 28th, 6 drugs, including Boryung Pharmaceutical’s 'Dukarb', Dong-A ST 'Growtropin II Inj’, Hanmi Pharmaceutical’s 'Rosuzet Tab', Janssen Korea’s 'Concerta Oros ER Tab’, Boehringer Ingelheim ‘Jardiance Duo Tab', and Daewoong Bio’s ‘Gliatamin’, have had their insurance price ceiling lowered for 3 consecutive years from 2022 to 2024 through the price-volume agreement Type C negotiations.

 

In this year's Type C negotiations, the prices of Boryung’s four Dukarb Tab items, which are combination antihypertensive drugs, were cut by -1.0% to -0.6%.

 

In the case of Dukarb Tab 30/10mg, the ceiling price had been KRW 715 in June 2022 but will become KRW 686 from the first of next month.

 

The company’s revenue from Dukarb has also increased significantly.

 

Based on UBIST, outpatient prescriptions of Dukarb Tab rose from KRW 40.5 billion in 2021 to KRW 54.3 billion last year.  Growth hormone drug Growtropin II Inj is another case where sales have increased significantly in recent years.

 

Based on IQVIA, its sales increased from KRW 36.7 billion in 2021 to KRW 69.8 billion in 2023.

 

five Growtropin II Inj items received a -5.0% to 0% reduction in their insurance ceiling price.

 

(Source: IQVIA (Growtropin II Inj only), UBIST for the rest)

Hanmi Pharmaceutical's four Rosuzet Tab items, a combination drug for hyperlipidemia, received a -1.5% to -1.3% reduction in their insurance ceiling price.

 

The outpatient prescription of Rosuzet Tab (UBIST) also surged from KRW127.8 billion in 2021 to KRW178.8 billion in 2023.

 

(Source: IQVIA (Growtropin II Inj only), UBIST for the rest)

Janssen Korea's ADHD drug Concerta Oros ER Tab also received a reduction in their insurance ceiling price for the third consecutive year through PVA negotiations.

 

This time, four of its items received a high rate of price reduction from -5.3% to -5.0%.

 

The drug also showed strong growth in outpatient prescriptions from KRW 15.1 billion in 2021 to KRW 22.8 billion last year (UBIST).

 

The insurance price ceiling of six Jardiance Duo Tab items, which is a combination used for diabetes, was reduced by -4.1% to -3.9%.

 

The drug recorded a high growth rate, from KRW 24.1 billion in 2021 to KRW 39.4 billion in 2023 in outpatient prescriptions (UBIST).

 

Sales of Gliatamin, a brain function enhancer, have continued to soar despite the reimbursement cut and clinical re-evaluations.

 

Outpatient prescriptions increased from KRW 114.3 billion in 2021 to KRW 154.5 billion last year (UBIST).

 

The price ceiling of Gliatamin Soft Cap and GliataminTab received a reduction of -3.3% this time (UBIST).

 

In the case of Gliatamin Soft Cap, the price was KRW 504 per tablet on January 1, 2022, but will drop to KRW 476 next month.

 

Over a three-year period, the reductions made in the insurance price ceiling amounted to -5.6%.

 

On the other hand, starting this year, the National Health Insurance Service will reduce the reduction rate in the reference formula by 30% for innovative pharmaceutical companies or companies with an R&D ratio of more than 10% for drugs that have been subject to PVA negotiations 3 times in 5 years.

 

This year, 17 items received a 30% reduction.